Lindahl Bertil, Lindbäck Johan, Jernberg Tomas, Johnston Nina, Stridsberg Mats, Venge Per, Wallentin Lars
Department of Medical Sciences and Cardiology, Uppsala Clinical Research Center, University Hospital, Uppsala, Sweden.
J Am Coll Cardiol. 2005 Feb 15;45(4):533-41. doi: 10.1016/j.jacc.2004.10.057.
The aim of this research was to describe N-terminal part of the pro-B-type natriuretic peptide (NT-proBNP) levels over time in non-ST-segment elevation acute coronary syndromes (NSTEACS), to elucidate factors associated with changes of NT-proBNP levels, and to examine association with long-term mortality.
The NT-proBNP levels are associated with mortality. Long-term temporal changes of NT-proBNP levels and their relation to other factors have not been examined.
The NT-proBNP was analyzed at randomization and at 48 h, after 6 weeks, 3 and 6 months in NSTEACS patients enrolled in the Fragmin and fast Revascularisation during InStability in Coronary artery disease (FRISC)-II trial. The NT-proB-type natriuretic peptide was analyzed at least three time points in 1,216 patients.
The median NT-proBNP level, which at randomization was 529 ng/l, decreased throughout the whole sampling period to 238 ng/l at six months. Elevated troponin T, C-reactive protein, and female gender were associated with higher reduction rates, and high age, diabetes, previous myocardial infarction, treatment with diuretics, and nitrates on admission with lower reduction rates. At each time point, the NT-proBNP level was predictive of the two-year mortality. However, the adjusted odds ratio increased for each time point.
The initial rise of NT-proBNP in NSTEACS is mainly reversible. Factors associated with less reversibility are related to chronically impaired left ventricular function, and factors associated with greater reversibility are related to the acute myocardial damage. The NT-proBNP level measured during a chronic, relatively stable phase is a better predictor of mortality than during an acute unstable phase. The clinical setting and timing of measurement will be important to consider when using NT-proBNP for risk assessment.
本研究旨在描述非ST段抬高型急性冠脉综合征(NSTEACS)患者中B型利钠肽原(NT-proBNP)N端部分水平随时间的变化,阐明与NT-proBNP水平变化相关的因素,并研究其与长期死亡率的关联。
NT-proBNP水平与死亡率相关。NT-proBNP水平的长期时间变化及其与其他因素的关系尚未得到研究。
在冠心病不稳定期使用法安明和快速血运重建(FRISC)-II试验中纳入的NSTEACS患者中,于随机分组时、48小时、6周、3个月和6个月时分析NT-proBNP。在1216例患者中至少在三个时间点分析了NT-proBNP。
随机分组时NT-proBNP水平的中位数为529 ng/l,在整个采样期内下降,6个月时降至238 ng/l。肌钙蛋白T升高、C反应蛋白升高和女性与更高的下降率相关,而高龄、糖尿病、既往心肌梗死、入院时使用利尿剂和硝酸盐治疗则与较低的下降率相关。在每个时间点,NT-proBNP水平均可预测两年死亡率。然而,每个时间点的校正比值比均升高。
NSTEACS中NT-proBNP的初始升高主要是可逆的。与可逆性较小相关的因素与慢性左心室功能受损有关,而与可逆性较大相关的因素与急性心肌损伤有关。在慢性相对稳定期测得的NT-proBNP水平比急性不稳定期更能预测死亡率。在使用NT-proBNP进行风险评估时,临床背景和测量时间很重要,需要考虑。